Skip to main content
CG $49.28 -4.14%
CG logo

CG · Carlyle Group Inc.

Track CG — free
$49.28 -2.13 (-4.14%) At close · Aug 14
Market Cap
$17.56B
Shares
356.33M
All earnings calls

Earnings call · FY2025 Q4

Carlyle Group Inc. Q4 FY2025 Earnings Call

Carlyle Group Inc. Q4 FY2025 Earnings Call

Concluded Feb 6, 2026 Audio replay
Feb 6, 2026 39:36 68 turns
Period
FY2025 Q4
Runtime
39:36
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Carlyle reported record full-year 2025 results, with fee-related earnings up 12% year over year, $54B of inflows versus an original $40B target, record AUM of $477B, and record transaction fees of $225M (+~40% YoY).

Global Credit and CLOs 50 IPO Exits and Monetizations 25 Global Wealth Distribution 23 Fundraising and Inflows 14 AlpInvest and Secondaries 8 Record Financial Performance 8

Management tone

Confident

Net tone +82 · low hedging

Grounding quotes
  • “2025 was a record year for The Carlyle Group Inc. We significantly outperformed the targets we identified at the beginning of the year.”
  • “This was the largest sponsor-backed IPO of all time, the largest healthcare IPO ever, and the largest IPO of 2025.”
  • “We enter 2026 with strong momentum.”
  • “We did the most originations we've ever done in credit in the past year in 2025 with almost $30 billion of originations.”

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $1.90B +84.1% YoY
Net income · derived Q4 $358.10M +69.8% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Record fee-related earnings up 12% YoY, materially exceeding original forecast, with record FRE margin of 47%
  • Inflows of $54B significantly outperformed original $40B target
  • Record transaction fees of $225M, up almost 40% YoY
  • Record AUM of $477B; $18B of capital returned to investors in both 2025 and 2024
  • Led IPO activity globally with ~$10B of issuance over the past two years, including Medline (largest sponsor-backed IPO of all time, >50% above IPO price)
  • Carlyle AlpInvest invested a record $14B and closed largest-ever secondary strategy at $20B; record 39 CLOs priced and ~$30B of credit originations in 2025

Risks & pressure points

  • Large flagship fundraises expected later in 2026 may be a headwind to fee-earning AUM and management fee growth in the near term, per analyst commentary on the call
  • Realization momentum could create headwinds to fee-earning AUM in the private equity segment as exits continue
  • Management declined to provide 2026 management fee or realization guidance ahead of the February 26 shareholder update

Key moments

Jump directly to management's words in the synchronized transcript.

“Fee-related earnings were a record $1.24 billion in 2025, a 12% organic growth rate, driven by sustained operating momentum across the firm. The full-year results significantly exceeded our initial guidance.” Justin Plouffe, CFO

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived
$203.70M
Dividend / share
$0.35
Full-screen source Call document